<DOC>
	<DOCNO>NCT00284973</DOCNO>
	<brief_summary>Shanghai Wanxing Bio-Pharmaceuticals currently evaluate one malaria vaccine candidate , PfCP2.9 adjuvanted Montanide ISA 720 . This trial design test safety immunogenicity 3 dose 2 vaccination schedule . This blood stage candidate malaria vaccine develop routine immunization infant child live malaria-endemic area .</brief_summary>
	<brief_title>A Study Safety Immunogenicity Malaria Vaccine Candidate</brief_title>
	<detailed_description>This double blind , randomize , control Phase I study PfCp2.9 , experimental malaria vaccine candidate , adjuvanted Montanide ISA 720 . The primary objective study assess safety reactogenicity vaccine healthy Chinese adult volunteer .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<criteria>Healthy male female ≥ 18 ≤ 45 year age Agrees donate blood course trial . Signed write informed consent provide . Available participate study duration . History allergic reaction follow vaccination . Involvement drug vaccine trial within four week prior trial . Acute illness within four week prior trial . Presence fever time vaccination , i.e . body temperature ( axillary ) &gt; 37.5 C. Presence chronic illness/disease include diabetes mellitus , tuberculosis , leprosy , epilepsy hypertension determine medical history examination . Persons systemic corticosteroid , immunomodulators anticoagulant within four week prior vaccination . Persons history allergic manifestation require treatment injectable antihistamine , adrenaline steroid . Pregnancy . Women pregnant , lactating , plan pregnancy throughout study period . A urinary pregnancy test ( immunochromatography ) perform woman childbearing potential entry prior vaccination . Adequate contraception throughout study use applicable . Sexually active woman use contraceptive . Current smoker ( ≥ 20 cigarettes/day ) . History malaria : person know history malaria positive marker antibody malaria parasite IFA and/or ELISA . History reside malaria endemic region malaria exposure ( travel ) within last two year . Abnormal hematology clinical chemistry consider clinically significant . Abnormal urine routine test consider clinically significant Persons positive marker HBV ( HBsAg ) and/or HCV ( AntiHCV ) infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>malaria</keyword>
</DOC>